Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis (NCT06982352)
Phase 1b Randomized, Double Blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of LPX-TI641 in Patients With Atopic Dermatitis and Psoriasis
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
Who can join: Review the eligibility criteria below.
Location: Red River Research Partners — Fargo, North Dakota
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Red River Research Partners — Fargo, North Dakota
- Clinical Investigations of Texas — Dallas, Texas
- Triumpharma Clinical Research Unit at AlEssra Hospital — Amman, Jordan
📞 Contact the Study Coordinator
Phone: (617) 203-5516
Email: anas.fathallah@lapixtherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis (AD)
- Effectiveness of Psychodermatologic Educational Modules on Atopic Dermatitis Patient Outcomes — Edmonton, Alberta
- A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Phoenix, Arizona
- Moisturization and Skin Hydration Study — Vancouver, British Columbia
- The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — Pittsburgh, Pennsylvania
- Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population — Aguascalientes, Aguascalientes
Explore by condition: All Atopic Dermatitis (AD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.